Litcius/Paper detail

Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models

Christina A. Wicker, Brian G. Hunt, Sunil Krishnan, Kathryn E. Aziz, Shobha Parajuli, Sarah Palackdharry, William R. Elaban, Trisha M. Wise‐Draper, Gordon B. Mills, Susan E. Waltz, Vinita Takiar

2021Cancer Letters97 citationsDOIOpen Access PDF

Topics & Concepts

RadioresistanceHead and neck squamous-cell carcinomaCancer researchGlutaminaseIonizing radiationGlutamineHead and neck cancerRadiation therapyCell cultureCancerChemistryMedicineInternal medicineBiologyIrradiationBiochemistryAmino acidPhysicsNuclear physicsGeneticsCancer, Hypoxia, and MetabolismGenomics, phytochemicals, and oxidative stressRNA modifications and cancer
Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models | Litcius